Although the underlying mechanisms of Gαi1/3-mediated NLGN3 signaling and glioma cell progression need further characterization, the results of the present and previous studies 26 strongly indicate that Gαi1 and Gαi3 could be valuable therapeutic targets for treating human glioma. This evidence concerns the gene NLGN3 and central nervous system cancer.